Phillips Edison & Company, a major owner of grocery-anchored shopping centers, will host a virtual business update on December 16, 2026. The webcast will provide insights into the company's strategy, long-term growth opportunities, and financial matters, featuring top executives including the CEO and CFO. Investors can access the live event and replay on the company's website. This update is important for stakeholders to understand PECO's future direction and performance outlook.
Phillips Edison & Company plans a virtual business update on December 16, 2026. For readers following the Real Estate sector, here is Pluang's market snapshot as of Nov 04, 2026 04:21 WIB: Of 47 priced Real Estate-sector US stocks tradable on Pluang, 21 rose and 26 fell today. Notable movers include AHR at USD 54.85 with a 1-day change of +1.97% and a typical hold time of 26 days, PLD at USD 127.29 down 1.82% with a typical hold time of 102 days and Pluang order activity showing 98% Sell / 2% Buy, and BEKE at USD 17.63 down 1.56% with a typical hold time of 26 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
